Diagnostic Utility of FGF-23 in Mineral Bone Disorder During Chronic Kidney Disease

Overview

Journal J Circ Biomark

Date 2022 Jan 13

PMID 35023876

Authors

Luisa Albanese

Gemma Caliendo

Giovanna DElia

Luana Passariello

Anna Maria Molinari

Claudio Napoli

Maria Teresa Vietri

Affiliations

Soon will be listed here.

Citing Articles

Carotid intima-media thickness, fibroblast growth factor 23, and mineral bone disorder in children with chronic kidney disease.

Palupi-Baroto R, Hermawan K, Murni I, Nurlita T, Prihastuti Y, Puspitawati I BMC Nephrol. 2024; 25(1):369.

PMID: 39433982 PMC: 11494757. DOI: 10.1186/s12882-024-03771-z.

Bone mineral density assessment in patients with cystinuria.

DAmbrosio V, Capolongo G, Caletti C, Vietri M, Ambrogio M, Lombardi G J Nephrol. 2024; 38(1):163-169.

PMID: 38963523 DOI: 10.1007/s40620-024-02012-8.

FGF-23 and sclerostin in serum and bone of CKD patients.

Lima F, Monier-Faugere M, Mawad H, David V, Malluche H Clin Nephrol. 2023; 99(5):209-218.

PMID: 36970967 PMC: 10286735. DOI: 10.5414/CN111111.

Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.

Vietri M, DElia G, Caliendo G, Albanese L, Signoriello G, Napoli C Genes (Basel). 2022; 13(2).

PMID: 35205366 PMC: 8872383. DOI: 10.3390/genes13020321.

References

Vasco M, Benincasa G, Fiorito C, Faenza M, De Rosa P, Maiello C . Clinical epigenetics and acute/chronic rejection in solid organ transplantation: An update. Transplant Rev (Orlando). 2021; 35(2):100609. DOI: 10.1016/j.trre.2021.100609. View

Isakova T, Xie H, Yang W, Xie D, Anderson A, Scialla J . Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305(23):2432-9. PMC: 3124770. DOI: 10.1001/jama.2011.826. View

Souberbielle J, Prie D, Piketty M, Rothenbuhler A, Delanaye P, Chanson P . Evaluation of a New Fully Automated Assay for Plasma Intact FGF23. Calcif Tissue Int. 2017; 101(5):510-518. DOI: 10.1007/s00223-017-0307-y. View

Angelin B, Larsson T, Rudling M . Circulating fibroblast growth factors as metabolic regulators--a critical appraisal. Cell Metab. 2012; 16(6):693-705. DOI: 10.1016/j.cmet.2012.11.001. View

Napoli C, Casamassimi A, Crudele V, Infante T, Abbondanza C . Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework. Future Cardiol. 2011; 7(4):485-97. DOI: 10.2217/fca.11.24. View

Ho B, Bergwitz C . FGF23 signalling and physiology. J Mol Endocrinol. 2020; 66(2):R23-R32. PMC: 8782161. DOI: 10.1530/JME-20-0178. View

Economidou D, Dovas S, Papagianni A, Pateinakis P, Memmos D . FGF-23 Levels before and after Renal Transplantation. J Transplant. 2010; 2009:379082. PMC: 2809417. DOI: 10.1155/2009/379082. View

Shimizu Y, Fukumoto S, Fujita T . Evaluation of a new automated chemiluminescence immunoassay for FGF23. J Bone Miner Metab. 2011; 30(2):217-21. DOI: 10.1007/s00774-011-0306-4. View

Hu M, Shiizaki K, Kuro-O M, Moe O . Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013; 75:503-33. PMC: 3770142. DOI: 10.1146/annurev-physiol-030212-183727. View

10.

Isakova T, Wahl P, Vargas G, Gutierrez O, Scialla J, Xie H . Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79(12):1370-8. PMC: 3134393. DOI: 10.1038/ki.2011.47. View

11.

Bellastella G, Maiorino M, De Bellis A, Vietri M, Mosca C, Scappaticcio L . Serum but not salivary cortisol levels are influenced by daily glycemic oscillations in type 2 diabetes. Endocrine. 2015; 53(1):220-6. DOI: 10.1007/s12020-015-0777-5. View

12.

Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K . Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69(11):1945-53. DOI: 10.1038/sj.ki.5000414. View

13.

Wolf M . Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012; 82(7):737-47. PMC: 3434320. DOI: 10.1038/ki.2012.176. View

14.

Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K . Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2009; 95(2):578-85. PMC: 2840849. DOI: 10.1210/jc.2009-1603. View

15.

Bergwitz C, Juppner H . Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010; 61:91-104. PMC: 4777331. DOI: 10.1146/annurev.med.051308.111339. View

16.

Takashi Y, Fukumoto S . FGF23 beyond Phosphotropic Hormone. Trends Endocrinol Metab. 2018; 29(11):755-767. DOI: 10.1016/j.tem.2018.08.006. View